Drug Trial Radar · NCT07937254
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of JAR-2203 in Healthy Participants With Elevated Plasma Lipoprotein(a)
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
44
Planned (sponsor's estimate)
Start
Oct 19, 2026
Primary completion
Jul 30, 2027
Study completion Nov 30, 2027
Sponsor
- Lead sponsor
- Beijing Jiake Ruikang Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This first-in-human Phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and effects on Lp(a) of single ascending doses of JAR-2203 in healthy adults with elevated Lp(a).
Conditions
- Lipid Metabolism Disorders
- Healthy Volunteers - Male and Female
- Hyperlipoproteinemia(a)
Interventions
JAR-2203Drug
JAR-2203 solution for injection given as a single subcutaneous injection; planned dose levels are 7.5, 30, 75, 150, 225, and 300 mg.
PlaceboDrug
Placebo for injection given as a single subcutaneous injection at a volume matched to the active treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experienced Treatment-emergent Adverse Events (TEAEs)Time frame: From first dose until the end of the study (through Day 169).
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.